Claim · 2018 · event · Stated in source · Supported

Generate Biomedicines' IPO prospectus (26 February 2026) states that "Flagship Pioneering founded Generate in 2018 as Flagship VL56, Inc."

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Generate Biomedicines → is stated to have been founded in → 2018

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Generate Biomedicinesis stated to have been founded in ↓2018

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2018 · event Records dated 2018 →

Scope and limitsA year as stated; it does not establish a legal incorporation date or a complete founder roster.

The evidence 01

primary sourceSupports the claim

Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock

Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Flagship Pioneering founded Generate in 2018 as Flagship VL56, Inc., working together with Dr. Gevorg Grigoryan, Ph.D., our founding Chief Technology Officer.”

Location in source Business, "Our Beginnings: Generate and Flagship Pioneering"

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Generate Biomedicines, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (22 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A6) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. A source states the organisation’s founding date or year, at the precision it gives. Neither legal incorporation nor a complete founder roster is implied.

Date. Year as stated by the prospectus; no month or day is given. The prospectus adds that in 2019 Flagship VL56, Inc. was combined with explorations from Flagship VL57, Inc.

Record ID aib-co-generate-founding-stated